Natural History of HTLV-I Infection: Prospective Follow-up of a Cohort of Blood Donors in Jamaica
NCT ID: NCT00339807
Last Updated: 2017-07-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1500 participants
OBSERVATIONAL
2002-01-17
2011-08-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Studies already completed or ongoing have shown notable differences in incidence and prevalence of HTLV-I associated diseases and underscore the need for comparative studies and analyses in these areas. This prospective new study of blood donors in Jamaica provides us with an opportunity to address many hypotheses regarding HTLV-I transmission and pathogenesis in the Caribbean in comparison with an ongoing cohort study of HTLV-I carriers in Japan.
This study will
* identify host factors associated with HTLV-I carrier status and HTLV-I pathogenesis.
* directly calculate the incidence of HTLV-I associated diseases in this population.
* examine the role of HTLV-I in the pathogenesis of other common infectious agents.
Approximately 5,000+ blood donors who came to the National Blood Transfusion each year will be screened for HTLV-I serology. Of those who agreed to participate, all HTLV-I carriers and age-, and sex-matched HTLV-I-negatives will be invited to the University of the West Indies clinic for a full study enrollment. Study participants will be given a standardized questionnaire, a full physical examination, and a phlebotomy (25-30 mL), and will be followed every other year for interim health status and additional phlebotomy. All subjects will receive an ophthalmologic examination for detection of uveitis and other ocular diseases. Some subjects will be further referred to a neurologist, hematologist or dermatologist, according to their signs and symptoms. Approximately 1200 HTLV-I carriers and 600 HTLV-I negatives will be recruited for a longitudinal follow-up over the next 5-year period. Two types of analyses will be conducted: comparison of HTLV-I-positive and HTLV-I-negative subjects, and comparison among HTLV carriers between those with a high level of viral load and those with a low level.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
B14 Meningococcal Carriage in Seine-Maritime Population: Prevalence Study and Search of Risk Factors
NCT00465582
Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma
NCT01765231
Mutations of the Pre-core Region of Hepatite B Virus (HBV)
NCT03625258
Viral Load Changes in Lymphoma Patients With HCV Infection After Chemotherapy
NCT02588560
Molecular Epidemiology of Hepatitis B in Cayenne General Hospital, French Guiana
NCT04886102
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The reported differences underscore the need for comparative studies in these endemic areas. In addition, analyses of larger, pooled data of HTLV-I carriers from different geographic areas are needed to ensure statistical power in studies of gene-environment interactions with extended use of molecular markers. However, existing population-based studies from Japan and the Caribbean are unfortunately no comparable with respect to the study subject's age and gender distributions. In order to address this issue, we proposed a study of blood donors in Jamaica, which enrolls a large number of both HTLV-I positive and HTLV-I negative, consisting of subjects that are more comparable to existing Japanese study with respect to age and sex. The proposed study will provide a basis for a comparative study of HTLV-I carriers in Japan and Jamaica and a comprehensive analysis of host genetic background of HTLV-I associated illnesses in the Black population.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
All HTLV-I positive donors and age-, sex-matched HTLV-1 negative donors (controls) will be enrolled.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of the West Indies
Kingston, , Jamaica
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9. doi: 10.1073/pnas.77.12.7415.
Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, Shirakawa S, Miyoshi I. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80. doi: 10.1073/pnas.78.10.6476.
Madeleine MM, Wiktor SZ, Goedert JJ, Manns A, Levine PH, Biggar RJ, Blattner WA. HTLV-I and HTLV-II world-wide distribution: reanalysis of 4,832 immunoblot results. Int J Cancer. 1993 May 8;54(2):255-60. doi: 10.1002/ijc.2910540216.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
02-C-N112
Identifier Type: -
Identifier Source: secondary_id
999902112
Identifier Type: -
Identifier Source: org_study_id
NCT00544661
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.